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The (R)- and (S)-enantiomers of quinuclidin-3-ol and quinuclidin-3-yl acetate as well as their
quaternary N-methyl and N-benzyl derivatives were synthesized in order to study the stereo-
selectivity of human erythrocyte acetylcholinesterase (EC 3.1.1.7) and plasma butyrylcholin-
esterase (EC 3.1.1.8). The compounds were tested as substrates and inhibitors of cholinesterases.
Both cholinesterases hydrolyze the derivatives of quinuclidin-3-yl acetate with a preference for
the (R)- over (S)-enantiomers. In contrast to the hydrolysis of the enantiomers of acetates, the
inhibition of acetylcholinesterase and butyrylcholinesterase by the (R)- and (S)-enantiomers of
quinuclidin-3-ol derivatives does not reveal enantiomeric preference of the enzymes. The (R)-
and (S)-acetates also act as nonstereoselective inhibitors of the enzyme-induced hydrolysis of
acetylthiocholine. The best substrate is (R)-N-methyl-3-acetoxyquinuclidinium iodide with kcat =
1.5 106 min–1 and kcat = 5.5 10
4 min–1 for acetylcholinesterase and butyrylcholinesterase, re-
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INTRODUCTION
Quinuclidine, 1-azabicyclo2.2.2octane, is a structural
feature of several natural and synthetic, physiologically
active compounds, many of which have been recognized
as pharmacological agents.1 Quinuclidine-3-ol and its
esters have been found to be of special interest. Quinu-
clidine-3-ol and its esters may be looked upon as bicyc-
lic analogues of acetylcholine, and therefore their inter-
action with acetylcholinesterase (AChE; EC 3.1.1.7) and
butyrylcholinesterase (BChE; EC 3.1.1.8) can be expect-
ed. Since inhibition of AChE by phosphorylation is a key
step in poisoning by organophosphorus (OP) compounds
such as pesticides and warfare agents, it is reasonable to
expect that these quinuclidine derivatives may interfere
in the poisoning process and act as potential antidotes. It
was previously found that quaternized quinuclidine-3-ol
and its conjugates with imidazolium and pyridinium ox-
imes were reversible inhibitors of AChE, while their car-
bamoylated derivatives progressively inhibited AChE.2,3
It was also shown that these compounds protected mice
against soman and tabun poisoning.4,5
Since quinuclidine-3-ol contains an asymmetric car-
bon atom, preparation of its esters leads to racemates. The
use of racemates of bioactive compounds requires cau-
tiousness since enantiomers can cause different biologi-
cal effects, from lower activity of one of the enantiomers
to increased toxicity of the unwanted enantiomer. There-
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fore, many chemical and some biocatalytic methods were
used for the separation of quinuclidine-3-ol derivatives.6,7
AChE and BChE revealed high stereoselectivity in
inhibition by chiral progressive inhibitors as well as in
their reactivation after being inhibited by chiral com-
pounds.8,9 The aim of this work was to study the stereo-
selectivity of AChE and BChE in reactions with enantio-
mers of quinuclidin-3-yl acetates as substrates as well as
in the reversible inhibition by enantiomers of quinucli-
din-3-ol derivatives (Figure 1). For that purpose (R)- and




Substrates included the synthesized (R)-3-acetoxyquinucli-
dinium L-tartarate dihydrate ((R)-QA), (S)-3-acetoxyquinu-
clidinium D-tartarate dihydrate ((S)-QA), (R)- and (S)-N-
methyl-3-acetoxyquinuclidinium iodides (MeQA), (R)- and
(S)-N-benzyl-3-acetoxyquinuclidinium chlorides (BzQA)
as well as commercially available acetylcholine perchlorate
(ACh) (BDH Chemicals Ltd., England) and acetylthiocho-
line iodide (ATCh) (Fluka-BioChemika, Switzerland) (Fig-
ure 1). Alcohols tested as inhibitors included the prepared
(R)- and (S)-quinuclidin-3-ols (QOH), (R)- and (S)-N-me-
thyl-3-hydroxyquinuclidinium iodides (MeQOH) and (R)- and
(S)-N-benzyl-3-hydroxyquinuclidinium chlorides (BzQOH)
(Figure 1). All quinuclidinium acetates were also tested as
inhibitors. Stock solutions of ACh and of acetates, as fur-
ther solutions, were prepared in 0.9 % sodium chloride.
Stock solutions of ATCh (0.1 M) were prepared in water
and those of quinuclidinium alcohols in 0.1 M phosphate
buffer, pH = 7.4; further solutions were also prepared in
phosphate buffer.
Synthesis of Compounds
General Remarks: Melting points were determined in open
capillaries using a Büchi B-540 melting point apparatus and
are uncorrected. Specific optical rotation values were deter-
mined with an Optical Activity LTD automatic polarimeter
AA-10 at 589 nm in methanol and ambient temperature
( 24 °C). Elemental analyses were performed with a Per-
kin-Elmer PE 2400 Series II CHNS/O Analyser. 1H and 13C
1D and 2D NMR spectra were recorded with a Varian XL-
GEM 300 spectrometer at ambient temperature. Chemical
shifts are given in ppm downfield from TMS as internal
standard.
(R)- and (S)-QOH were prepared from the commercial-
ly available racemic QOH. Esterification of racemic QOH
with acetic anhydride produced the racemic acetate (QA).
QA was treated with L- or D-tartaric acid to obtain diaste-
reomeric mixtures.10 Diastereoisomers were separated by
several recrystallizations and then hydrolyzed with aqueous
sodium hydroxide to obtain pure QOH enantiomers. (R)-
and (S)-QOH were then the starting compounds in the prep-
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Figure 1. Structures and abbreviations of the quinuclidinium de-
rivatives, acetylcholine and acetyltiocholine.
aration of quaternary (R)- and (S)-MeQOH using methyl io-
dide as a quaternization agent.2,10 Compounds (R)-BzQOH
m.p. 230.2–231.3 °C, D
25 = –23.3° (c = 3.0; MeOH) and
(S)-BzQOH m.p. 229.8–230.3 °C, D
25 = +24.1° (c = 3.0;
MeOH) were prepared using the method previously de-
scribed in the synthesis of the racemic salt.11 ESMS: m/z
(C14H20NO+, calcd. 218.31) found 218.4. 1H NMR (DMSO-
d6) /ppm: 1.60–2.05 (m, 5H, H5, H8 and H4); 3.01–3.11
(m, 1H, H2); 3.24–3.45 (m, 4H, H6 and H7); 3.61–3.71 (m,
1H, H2); 3.90–4.10 (m, 1H, H3); 4.45–4.56 (m, 2H, –CH2–
Ph); 5.77 (d, 3J = 3.5 Hz, 1H, –OH), 7.48–7.52 (m, 5H, Ph).
13C NMR (DMSO-d6) /ppm: 17.73 (C5); 20.21 (C8); 28.55
(C4); 51.99 (C6); 53.98 (C7); 59.25 (C2); 65.12 (–CH2–Ph);
67.67 (C3); 127.34 (C1 Ph); 129.28 (C3, C5 Ph); 130.44 (C4
Ph); 133.54 (C2, C6 Ph).
Anal. Calcd. for C14H20ClNO (Mr = 253.77): C 66.26,
H 7.94, N 5.52; found: C 66.50, H 8.08, N 5.75 %.
Compounds (R)-BzQA m.p. 204.2–205.3 °C, D
25 =
–11.9° (c = 3.0; MeOH) and (S)-BzQA m.p. 204.5–205.1
°C, +12.3° (c = 3.0; MeOH) were prepared by the addition
of two equivalents of benzyl bromide to the solution of the
appropriate chiral quinuclidin-3-yl acetate in dry acetone.
Precipitated white crystals were repeatedly washed with dry
ether (yield 96 %), ESMS: m/z (C16H22NO2+, calcd. 260.16)
found 260.1. 1H NMR (DMSO-d6) /ppm: 1.78–2.13 (m, 4H,
H5, H8); 2.08 (s, 3H, CH3C=O); 2.21–2.29 (m, 1H, H4);
3.35–3.60 (m, 5H, H6, H7 and H2); 3.84 (dd, 1H, H2 2J = 14.5
and 3J = 8.2 Hz); 4.57–4.69 (m, 2H, –CH2–Ph); 4.80–5.10
(m, 1H, H3); 7.52–7.57 (m, 5H, Ph). 13C NMR (DMSO-d6)
/ppm: 17.94 (C5); 20.56 (C8); 28.87 (C4); 24.14 (CH3C=O);
52.27 (C6); 53.72 (C7); 59.62 (C2); 65.74 (–CH2–Ph); 67.28
(C3); 127.63 (C1 Ph); 129.05 (C3, C5 Ph); 130.27 (C4 Ph);
133.19 (C2, C6 Ph); 170.10 (C=O).
Anal. Calcd. for C16H22BrNO2 (Mr = 340.26): C 56.48,
H 6.52, N 4.12; found: C 57.11, H 6.34, N 4.22 %.
Enzyme Sources
Sources of AChE and BChE were native human erythrocy-
tes and native human plasma, respectively. Blood was taken
from two healthy donors with the usual plasma BChE phe-
notype, which was determined according to the standard
phenotyping procedure.12 Blood was taken into tubes con-
taining heparin, centrifuged for 20 min at 2500 r.p.m. and
plasma was then separated from erythrocytes. For substrate
hydrolysis experiments, erythrocytes were washed twice and
diluted with 0.9 % sodium chloride to the original blood
volume. Erythrocytes were then haemolysed with an equal
volume of distilled water and frozen. For inhibition experi-
ments, erythrocytes were washed twice and diluted with phos-
phate buffer to the original blood volume.
Substrate Hydrolysis
Enzyme hydrolysis of the (R)- and (S)-enantiomers of QA,
MeQA and BzQA, and of acetylcholine was measured by
an adapted pH-stat method originally described by Jensen-
Holm et al.13 The principle of the method is following. The
acetic acid, the product of the enzyme hydrolysis of an ace-
tate is titrated at constant pH = 7.4 with sodium hydroxide
of known concentration. Volume of the delivered NaOH
should be recorded during the reaction. The amount of the
delivered NaOH is equal to the amount of acetic acid pro-
duced and that is equall to the amount of the hydrolysed ace-
tate used as substrate. Our measurements were performed
on a 718 STAT Titrino (Metrohm) with a combined pH glass
LL microelectrode. The titration solution was 5.0  10–3 M
NaOH; 0.2 M NaOH was prepared from Titrival NaOH
(Kemika, Croatia) and then diluted to 5.0  10–3 M NaOH
with distilled water free of CO2. All measurements and solu-
tions were prepared in 0.9 % NaCl solution. When the tem-
perature equilibration (37 °C) was achieved, the reaction
medium, containing erythrocytes or plasma was adjusted to
pH = 7.4. Erythrocytes were finally diluted 40–240-fold
(usually 240-fold) with 0.9 % NaCl. The final dilution for
plasma BChE during the enzyme assay was 30- to 300-fold
(usually 150-fold). The reaction was started by adding the
substrate (0.25–1.0 mL). The total volume of the reaction
mixture was 6.0 mL. Reading of the delivered NaOH per
time was stopped after 5 min. Activities were calculated
from the volume of 5.0  10–3 M sodium hydroxide deliv-
ered per minute. Activity was expressed as the amount of
substrate hydrolised per minute (mol min–1) per millilitre
of blood (for erythrocytes) or per millilitre of plasma. All
activities were corrected for spontaneous hydrolysis of the
substrates. All solutions were degassed before experiments.
Enzyme Inhibition
Inhibition of the enzymes by alcohols and acetates was mea-
sured with acetylthiocholine (ATCh) as substrate. All expe-
riments were done in 0.1 M phosphate buffer, pH = 7.4, at
37 °C. The enzyme activity towards ATCh was measured
by the Ellman spectrophotometric method using DTNB as
the thiol reagent.14 The increase of absorbance was followed
at 412 nm. Measurements were done on a spectrophotome-
ter (Cary III, Varian Inc., Australia) with an on-line com-
puter provided with the software Cary Win UV Kinetics
Application, Varian Australia Pty Ltd, Sax Software Corp,
Software version 02.00(26). The following procedure was
applied: suspensions of washed erythrocytes diluted to the
original blood volume or plasma (0.3 mL and 0.1 mL, re-
spectively) diluted in buffer were mixed with 0.10 mL in-
hibitor and DTNB (final concentration 0.33 mmol dm–3).
ATCh (0.1 mL) was added to the mixture and the absorban-
ce was recorded for 3 min starting 30 s after the reagents
were thoroughly mixed. Control samples contained buffer
instead of inhibitor. Suspension of erythrocytes was diluted
600-fold and measurements were done against a blank that
contained the erythrocyte suspension and DTNB in buffer.
Final dilution of plasma BChE during the enzyme assay was
300-fold, and a solution of DTNB in buffer was used as a
blank. All activities were corrected for spontaneous hydro-
lysis of ATCh. Final ATCh concentrations were from 0.05
to 10 mmol dm–3. Concentrations of alcohols and acetates
were 0.075–40 mmol dm–3 and 0.04–20 mmol dm–3, respec-
tively.
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Catalytic Constants
The pS-curves of AChE and BChE were analyzed by apply-













where  is the enzyme activity at the given substrate con-
centration S, Vmax is the maximum rate of substrate hy-
drolysis, KM is the Michaelis constant, and Kss is the sub-
strate inhibition constant.
Enzyme-inhibitor Dissociation Constants
The constants were evaluated from the kinetics of competi-
tion between ATCh and inhibitors for AChE or BChE. Ac-
tivities of the enzymes were measured at different substrate
concentrations (S) in the absence (0) and presence (I) of
the given inhibitor concentration (I). For each substrate
concentration, the apparent dissociation constant (Kapp) was
calculated. The enzyme-inhibitor dissociation constants were


















If the relationship between Kapp vs. S is linear, the in-
tercept on the ordinate K(I) is either the enzyme-inhibitor
dissociation constant for the catalytic site (Ka) or the disso-
ciation constant for the peripheral site (Ki). The distinction
between Ka and Ki was based on the numerical values of
K(S), which is the intercept of the line on the abscissa of the
Hunter-Downs plot (Eq. 2). The K(S) constants in the Hunter-
Downs equation correspond either to the dissociation con-
stants of the enzyme-substrate Michaelis complex that could
be approximated to the Michaelis constant (KM) or dissoci-
ation constants of the enzyme-substrate complex when two
molecules of substrate are bound to the enzyme (Kss).
If an inhibitor binds to both sites of an enzyme, Kapp is a
non-linear function of the substrate concentration. In this
case, Ka can be calculated from Kapp values determined at low
substrate concentrations, and Ki from Kapp values determined
at higher substrate concentrations. At low substrate concen-
trations, inhibitors are expected to compete for the catalytic
site (Ka), and at higher substrate concentrations for the pe-
ripheral site (Ki), the corresponding K(S) values being KM and
Kss, respectively.16 The peripheral anionic site of cholineste-
rases is located at the rim of the active site gorge and is cru-
cial for dictating the specificity of ligands. Occupation at this
site may affect the conformation of the active centre.
RESULTS
Synthesis of Chiral Quinuclidinium Derivatives
Enantiomers of QOH were prepared in three steps. In
the first step, the racemic QOH was esterified with ace-
tic anhydride to obtain the racemic acetate, which was
then transformed to diastereomeric mixtures using L- or
D-tartaric acids.10 Diastereoisomers were separated by
recrystallization and then hydrolyzed with aqueous so-
dium hydroxide to obtain (R)- and (S)-QOH. (R)- and
(S)-QA were then prepared from (R)- and (S)-QOH us-
ing acetic anhydride as an esterification agent. Quater-
nary (R)- and (S)-MeQOH were obtained from the same
alcohols by a previously described quaternization proce-
dure using methyl iodide as a quaternization agent.2,10
Quaternary (R)-BzQOH and (S)-BzQOH were also pre-
pared from (R)- and (S)-QOH following the quaterniza-
tion procedure reported for the synthesis of racemic
BzQOH.11 Enantiomers of BzQA were obtained from
(R)- and (S)-QA by using benzyl bromide as a quaterni-
zation agent.
Synthesized compounds were characterized, identi-
fied, and their purity was established by 1H NMR, 13C
NMR and MS spectroscopies, elemental analyses and by
determining the melting points and optical rotation values.
Hydrolysis of the Acetates
All (R)-derivatives were hydrolyzed by both AChE and
BChE while (S)-acetates were not hydrolyzed. The only
exception was (S)-MeQA, which was a very poor sub-
strate of AChE. The activities of AChE were measured
with substrate concentrations between 0.5 and 20 mmol
dm–3 and those of BChE between 1.0 and 10 mmol dm–3
(Figure 2). The activity measurement at lower substrate
concentrations was not reliable, so only approximate va-
lues of some constants could be determined (Table I). The
best substrate for both enzymes was (R)-MeQA. Maxi-
mum activities of AChE and BChE for this substrate
were about 70 % and 60 %, respectively, compared to
the maximum activities obtained with ACh as substrate.
All KM and Kss values of AChE were higher for quinu-
124 A. BOSAK et al.
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Figure 2. Concentration dependence of (R)-MeQA hydrolysis (v)
by AChE () and BChE (). Points represent the mean values of
three measurements on average.
clidinium compounds than for ACh. KM values of BChE
were lower for (R)-MeQA and (R)-BzQA than for ACh.
The kcat for acetates were calculated from Vmax val-
ues obtained for the acetates in this paper, and the con-
centration of AChE in human blood (3 nmol dm–3) and
BChE in serum (60 nmol dm–3) reported in the litera-
ture.17 For the best substrate, (R)-MeQA, kcat values are
1.5  106 min–1 and 5.5  104 min–1 for AChE and BChE,
respectively.
Inhibition of the ATCh Hydrolysis by Chiral
Quinuclidin-3-ol Derivatives
The Hunter-Downs plots of the reversible inhibition of
AChE and BChE by the enantiomers of quinuclidin-3-ol
derivatives displayed curves for both enzymes that indi-
cated competition between the inhibitors and ATCh at
two sites of the enzymes (Figure 3). A linear relationship
between the apparent dissociation constants and the sub-
strate was obtained only for AChE and (R)-BzQOH. We
considered two phases of competition: one at lower ATCh
concentrations (up to 1 mmol dm–3) and the other at
higher concentrations. Ka, Ki, KM and Kss constants were
determined for the substrate concentration ranges de-
noted (Table II).
The Ka or Ki constants for enantiomeric pairs do not
differ much for any of the alcohols (Table II). For most
compounds, however, the Kapp values for the enantiomers
differ significantly at higher ATCh concentrations, as it
was shown for BChE and the (R)- and (S)-BzQOH (Fig-
ure 3). The strongest inhibitors (with the lowest dissoci-
ation constants) for both enzymes were both BzQOH en-
antiomers, with a slightly higher affinity of (S)- than of
(R)-enantiomer for enzymes (Table II).
KM and Kss values obtained from the Hunter-Downs
plot (Table II) are not the same but tend to the values of
the respective constants obtained in the absence of an in-
hibitor (Table I).
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(R)-QA 0.80 ± 0.10 >20(b) 3.0 ± 0.1 6.5 ± 1.1 1.1 ± 0.1
(S)-QA – – – – –
(R)-MeQA 0.2(b) 39 ± 7 4.4 ± 0.2 0.57 ± 0.06 3.3 ± 0.0
(S)-MeQA 0.5(b) – 0.3(b) – –
(R)-BzQA <0.5(b) 34 ± 7 2.6 ± 0.1 0.2(b) 0.6(b)
(S)-BzQA – – – – –
ACh 0.1(b) 24 ± 3 6.0 ± 0.2 1.3 ± 0.4 5.7 ± 0.4
ATCh 0.05 ± 0.02 13 ± 2 6.2 ± 0.4 0.38 ± 0.09 5.5 ± 0.1
(a) Activities of AChE are expressed per mL of whole blood and those of BChE per mL of plasma.
(b) Approximately estimated values.








































Figure 3. Inhibition of AChE by (R)-MeQOH () and (S)-MeQOH
() and BChE by (R)-BzQOH (), (S)-BzQOH (). Activities were
measured with acetythiocholine as substrate. Points represent the
Kapp values of six measurements on average.
Inhibition of the ATCh Hydrolysis by (R)- and
(S)-Quinuclidine Acetates
Inhibition by the acetate enantiomers proceeded in the
same way as the inhibition by alcohols. The competitive
inhibition presented in the Hunter-Downs plot gave straight
lines in the range of ATCh concentration between 0.1 to
1.0 mmol dm–3 (Table III). The acetates were poor inhib-
itors of the acetylthiocholine hydrolysis catalyzed by
AChE and BChE. The stereoselectivity of the enzymes
was not manifested in the inhibition by the acetate enan-
tiomers.
DISCUSSION
It was shown earlier that the stereoselectivity of hydro-
lysis catalyzed by AChE from Electrophorus electricus
was in favour of the (R)-enantiomer in the case of (R)-
and (S)-quinuclidin-3-yl acetates and their N-methyl de-
rivatives.18 BChE was used for the resolution of racemic
quiniclidin-3-yl butyrate.7 Although BChE-induced hy-
drolysis was also in favour of the (R)-enantiomer, the
difference in hydrolysis rates was not sufficient to achie-
ve complete resolution of the enantiomers. Furthermore,
BChE from horse serum can be employed in stereoselec-
tive hydrolyses of quiniclidin-3-yl-benzoates and their
N-methyl and N-benzyl derivatives.19,20
Our results do not show a qualitative difference be-
tween AChE and BChE in their reactions with the qui-
nuclidine acetates or with their alcohol derivatives. Both
AChE and BChE revealed in hydrolysis exclusive pref-
erence for the (R)- over (S)-acetates. The (R)-compounds
evidently fit better into the active site of both enzymes
than (S)-enantiomers. In general, all (R)-compounds were
better substrates of AChE than BChE. (R)-N-methyl ace-
tate was the best substrate among the tested quinuclidi-
nium acetates for both enzymes.
Primo`i~ et al.19–21 studied the hydrolysis of the en-
antiomers of tertiary and quaternary N-methyl- and N-
benzylquinuclidin-3-yl benzoates catalyzed by the horse
serum BChE. They also found the preference for the hy-
drolysis of (R)- over that of (S)-enantiomers. The au-
thors calculated the relative energies of the species in-
volved in the hydrolytic process and analyzed their ge-
ometries in the constructed model of the active site of
human BChE. These results indicate that hydrolysis is
affected, to an appreciable extent, by a proper geometric
orientation of substrates at the choline subsite of the en-
zyme, which serves as a recognition site of the substra-
te’s quaternary ammonium groups. The main difference
in binding of quinuclidinium and choline esters was found
in the ammonium electrostatic region, which includes
the cation--interaction of the ammonium moiety of
substrates with the indole ring of Trp84. The important
cation--interaction with Trp84 was lower in the case of
the (S)-enantiomer of N-benzylquinuclidinium benzoate
and that, as well as the steric limitations (accommoda-
tion of the benzyl group), could be the main explanation
for the slower rate of the (S)-enantiomer hydrolysis.20 In
126 A. BOSAK et al.
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(a) Dissociation constants of enzyme-inhibitor complexes Ka and Ki and
catalytic constants KM and Kss were obtained from six experiments on
average in the listed range of acetylthiocholine (ATCh) concentrations.
Relative standard deviations of the Ka and Ki values were 19 % and
those of KM and Kss, 23 %.
(b) ATCh = 0.10–1.0 mmol dm–3.
(c) ATCh = 1.0–10 mmol dm–3.








(S)-QA 0.10 – 5.0 8.8(b) 2.2(b)
(S)-MeQA 0.10 – 1.0 0.61 0.22
(S)-MeQA 1.0 – 10 2.8(b) 2.8(b)
(S)-BzQA 1.0 – 10 0.14 0.63
(R)-MeQA(c) 0.10 – 1.0 0.3 0.1
(R)-BzQA(c) 0.10 – 1.0 0.4 0.4
Butyrylcholinesterase
(S)-QA 0.10 – 1.0 2.8 0.18
(S)-MeQA 0.10 – 1.0 1.8 0.10
(S)-BzQA 1.0 – 10 0.07 0.30
(R)-MeQA(c) 0.10 – 1.0 0.8 0.1
(R)-BzQA(c) 0.10 – 1.0 0.1 0.1
(a) Dissociation constants of enzyme inhibitor complexes Ka and Ki and
catalytic constants KM and Kss were obtained on average from three
experiments in the listed range of acetylthiocholine (ATCh) concentra-
tions. Relative standard deviations of the constants for (S)-compounds
were 33 %.
(b) The values refer to Ki and Kss, respectively.
(c) Approximately estimated values.
the case of the tertiary (S)-enantiomers, it was shown
that no strong interaction with the choline domain ex-
isted in the orientation of the complex necessary for the
reaction.19,21 Therefore, it can be assumed that the acy-
lation step is additionally rate limited by the free energy
spent on the pre-organization of (S)-ligands. The same
explanations for the difference in the interaction of (R)-
and (S)-enantiomers could be assumed for the deriva-
tives of the quinuclidine acetates studied in this paper.
All tested quinuclidinium alcohols and acetates are
competitive inhibitors of both AChE and BChE. The
Hunter-Downs plot shows that alcohols bind to two sites
of the enzymes, catalytic and peripheral sites. The affini-
ties of both enzymes for the alcohols increase in the or-
der QOH < MeQOH < BzQOH.
Contrary to the hydrolysis of quinuclidine acetates,
there is no enantioselectivity or it is hardly manifested in
the reversible inhibition of the enzymes by the quinucli-
dinium alcohols and acetates. Demands for steric ac-
commodation of acylating cholinesterase substrates are
more restrictive than those for the inhibition by revers-
ible inhibitors. Acylating substrates or inhibitors, such as
organophosphorus compounds, should be favourably ac-
commodated in the active centre acyl pocket considered
to be the main component of the enzyme active centre
asymmetry.8,9,22 Reversible inhibitors have more freedom
to rotate within the active site gorge, and probably for
this reason the enantioselectivity of the cholinesterases
toward certain reversible inhibitors was found to be much
lower than that found for covalent chiral inhibitors.23
In this paper, both human native AChE and BChE
were shown to be very strongly stereoselective in the re-
action with quinuclidine acetates. Therefore, both enzy-
mes could be used in the stereoselective preparation of
this class of compounds as well as for preparation of en-
antiomers of other esters of quinuclidin-3-ols.
Acknowledgements. – Part of this paper is from the M.Sc.
thesis of A. B. The study was supported in part by grants No.
0022014 and 0119610 of the Ministry of Science, Education
and Sports of the Republic of Croatia.
REFERENCES
1. M. D. Mashovsky, L. N. Yakhontov, M. E. Kaminka, and E.
E. Mikhlina, Prog. Drug. Res. 27 (1983) 9–61.
2. E. Reiner, M. [krinjari}-[poljar, S. Dunaj, V. Simeon-Ru-
dolf, I. Primo`i~, and S. Tomi}, Chem. Biol. Interact. 119–
120 (1999) 173–181.
3. V. Simeon-Rudolf, E. Reiner, M. [krinjari}-[poljar, B. Ra-
di}, A. Luci}, I. Primo`i~, and S. Tomi}, Arch. Toxicol. 72
(1998) 289–295.
4. I. Primo`i~, R. Od`ak, S. Tomi}, V. Simeon-Rudolf, and E.
Reiner, J. Med. Chem. Def., http://www.jmedchemdef.org,
2 (2004) 1–30.
5. B. Radi}, A. Luci}, M. Peraica, A.-M. Domijan, and V. Bra-
damante, Acta. Pharm. 51 (2001) 1–9.
6. B. Ringdahl, R. S. Jope, and D. J. Jenden, Biochem. Phar-
macol. 33 (1984) 2819–2822.
7. M. Rehavi, S. Maayani, and M. Sokolovsky, Life Sci. 21
(1977) 1293–1302.
8. Z. Kovarik, Z. Radi}, H. A. Berman, V. Simeon-Rudolf, E.
Reiner, and P. Taylor, Biochem. J. 373 (2003) 33–40.
9. Z. Kovarik, Z. Radi}, H. A. Berman, V. Simeon-Rudolf, E.
Reiner, and P. Taylor, Biochemistry 43 (2004) 3222–3229.
10. B. Ringdahl, B. Resul and R. Dahlbom, Acta Pharm. Suec.
16 (1979) 281–283.
11. A. Kalir, E. Sali, and E. Shirin, Isr. J. Chem. 9 (1971) 267–
268.
12. V. Simeon-Rudolf and R. T. Evans, Acta Pharm. 51 (2001)
289–296.
13. J. Jensen-Holm, H. H. Lausen, K. Milthers, and O. Møller,
Acta Pharmacol. Toxicol. 15 (1959) 384–394.
14. G. L. Ellman, K. D. Courtney, V. Andres, and R. M. Feat-
herstone, Biochem. Pharmacol. 7 (1961) 88–95.
15. M. Dixon and E. C. Webb (Eds.), Enzymes, 3rd ed., Aca-
demic Press, New York, 1979, pp. 126–132.
16. W. N. Aldridge and E. Reiner, Enzyme inhibitors as sub-
strates. Interaction of esterases with esters of organophos-
phorus and carbamic acids, in: E. L. Tatum and I. A. Neu-
berger (Eds.), Frontiers in Biology, Vol. 26, North-Holland,
Amsterdam, 1972.
17. O. Lockridge and P. Masson, Neurotoxicology 21 (2000)
113–126.
18. G. Lambrecht, Arch. Pharm. 315 (1982) 646–651.
19. I. Primo`i~, T. Hrenar, S. Tomi}, and Z. Mei}, J. Phys. Org.
Chem. 15 (2002) 608–614.
20. I. Primo`i~, T. Hrenar, S. Tomi}, and Z. Mei}, Eur. J. Org.
Chem. (2003) 295–301.
21. I. Primo`i~, T. Hrenar, S. Tomi}, and Z. Mei}, Croat. Chem.
Acta 76 (2003) 93–99.
22. A. Ordentlich, D. Barak, G. Sod-Moriah, D. Kaplan, D. Miz-
rahi, Y. Segall, Ch. Kronman, Y. Karton, A. Lazar, D. Mar-
cus, B. Velan, and A. Shafferman, Biochemistry 43 (2004)
11255–11256.
23. G. [inko, Z. Radi}, P. Taylor, V. Simeon-Rudolf, and E. Rei-
ner, Kinetics of interaction of ethopropazine enantiomers
with butyrylcholinesterase and acetylcholinesterase, in: I.
Silman, H. Soreq, L. Anglister, D. Michaelson, and A. Fisher
(Eds.), Cholinergic Mechanisms: Function and Dysfunc-
tion, Taylor and Francis, London, 2004, pp. 795–796.
CHOLINESTERASES AND QUINUCLIDIN-3-OL DERIVATIVES 127
Croat. Chem. Acta 78 (1) 121–128 (2005)
SA@ETAK
Enantiomeri kinuklidin-3-ol derivata: Razdvajanje enantiomera i interakcija
s ljudskim kolinesterazama
Anita Bosak, Ines Primo`i~, Mislav Or{uli}, Sr|anka Tomi} i Vera Simeon-Rudolf
Prire|eni su (R)- i (S)-enantiomeri kinuklidin-3-ola i kinuklidin-3-il-acetata te odgovaraju}i kvaterni N-me-
tilni i N-benzilni derivati kako bi se prou~ila njihova interakcija s ljudskom eritrocitnom acetilkolinesterazom
(EC 3.1.1.7) i butirilkolinesterazom iz plazme (EC 3.1.1.8). Spojevi su studirani kao supstrati i inhibitori tih
enzima. Obje kolinesteraze pokazuju visoku stereoselektivnost pri hidrolizi kinuklidin-3-il acetata preferiraju}i
(R)- u odnosu na (S)-enantiomere. Nasuprot hidrolizi enantiomera acetatnih derivata, inhibicija acetilkolinesteraze
i butirilkolinesteraze s (R)- i (S)-enantiomerima kinuklidin-3-ola i kinuklidin-3-il-acetata te njihovih N-metilnih i
N-benzilnih derivata, ne pokazuje stereoselektivnost tih enzima. Kao najbolji supstrat za oba enzima pokazao
se (R)-N-metilkinuklidinijev acetat, s kcat = 1,5  10
6 min–1 za acetilkolinesterazu, odnosno kcat = 5,5  10
4 min–1
za butirilkolinesterazu. (R)- i (S)-N-benzilkinuklidinijevi derivati bili su najja~i inhibitori za te enzime.
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